

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 1 of 12, Revision date: 22/10/2023

## SECTION 1 : IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1 Product identifier:

**Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor**

CAS No.:

Index No:

EC No:

REACH No:

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses: Use of the substance or mixture for Laboratory Research use only ;

Uses advised against: Do not use for diagnostics, therapeutics or other clinical uses. ;

### 1.3 Details of the supplier of the safety data sheet:

#### Supplier:

Name: CISBIO BIOASSAYS, company of Revvity Group - CBBIOA -

Address: Parc Marcel Boiteux - BP 84175 - 30200 Codolet, France

Phone : +33 4 66 79 67 05 - Fax : +33 4 66 79 67 50

E-Mail (competent person):  codolet.sds@revvity.com

### 1.4 EMERGENCY TELEPHONE NUMBER:

France - Numéro ORFILA (INRS) : + 33 (0)1 45 42 59 59

Ce numéro permet d'obtenir les coordonnées de tous les centres Anti-poison Français. Ces centres anti-poison et de toxicovigilance fournissent une aide médicale gratuite (hors coût d'appel), 24 heures sur 24 et 7 jours sur 7.

USA & Canada - Phone: 1-888-963-456 (1)

Other countries - Phone: +33 (0) 466 796 737 (2)

<https://www.cisbio.com>

<https://www.revvity.com>

(1) Available from Monday to Thursday 8:30 am to 5:30pm GMT-5 and Friday: 8:30 am to 3:00pm GMT-5

(2) Available from Monday to Friday 9:00 am to 5:30 pm GMT+2

## SECTION 2 : HAZARDS IDENTIFICATION

### 2.1 Classification of the substance or mixture:

Classification according to Regulation (EC) No 1272/2008 [CLP]	Category code	Hazard statement	Precautionary statement
The substance or mixture is not classified as hazardous under the CLP Regulation (EC) No 1272/2008	None	None	None

### 2.2 Label elements

Labelling according to Regulation (EC) No 1272/2008 [CLP/GHS]

#### Product identifier:

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Substances contained in this product:

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 2 of 12, Revision date: 22/10/2023

---

Hazard pictograms

Signal word:

Hazard and precautionary statements:

### **2.3 Other hazards**

The mixture does not contain substances classified as 'Substances of Very High Concern' (SVHC)  $\geq 0.1\%$  published by the European Chemicals Agency (ECHA) under article 57 of REACH. The mixture satisfies neither the PBT nor the vPvB criteria for mixtures in accordance with annexe XIII of the REACH regulations EC 1907/2006. ;

Adverse human health effects and symptoms:

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 3 of 12, Revision date: 22/10/2023

## SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

### 3.2 Mixtures

#### Hazardous ingredients:

This mixture does not contain any hazardous substances at the concentration limits given in Regulation (EC) No. 1272/2008 and OSHA Hazard Communication Standard 29 CFR 1910.1200.

#### Additional information:

Full text of H- and EUH-phrases: see SECTION 16.

## SECTION 4 : FIRST AID MEASURES

### 4.1 Description of first aid measures

**General information:** Do not leave affected person unattended. ; Remove affected person from the danger area and lay down. ;

**Following inhalation:** In case of respiratory tract irritation, consult a physician. ; Provide fresh air. ;

**Following skin contact:** After contact with skin, wash immediately with water ; Remove contaminated clothing ;

**Following eye contact:** After contact with the eyes, rinse with water with the eyelids open for a sufficient length of time, then consult an ophthalmologist immediately. ;

**Following ingestion:** Do NOT induce vomiting. ; Give nothing to eat or drink. ; If accidentally swallowed rinse the mouth with plenty of water (only if the person is conscious) and obtain immediate medical attention. ;

**Self-protection of the first aider:**

### 4.2 Most important symptoms and effects, both acute and delayed

Symptoms: No known symptoms to date. ;

Effects:

### 4.3 Indication of any immediate medical attention and special treatment needed

Notes for the doctor:

## SECTION 5 : FIREFIGHTING MEASURES

### 5.1 Extinguishing media:

**Suitable extinguishing media:** This product is not flammable. Use extinguishing agent suitable for type of surrounding fire ;

### 5.2 Special hazards arising from the substance or mixture

Hazardous combustion products: /

### 5.3 Advice for fire-fighters

Wear Protective clothing. ;

## SECTION 6 : ACCIDENTAL RELEASE MEASURES

### 6.1 Personal precautions, protective equipment and emergency procedures

Emergency procedures: Provide adequate ventilation. ; Emergency procedures: Remove persons to safety. ; Personal precautions: Use personal protection equipment (see section 8). ;

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 4 of 12, Revision date: 22/10/2023

## 6.2 Environmental precautions

Do not allow to enter into surface water or drains. ; Ensure all waste water is collected and treated via a waste water treatment plant. ;

## 6.3 Methods and material for containment and cleaning up

For cleaning up: Suitable material for taking up: Absorbing material, organic ;

Other information:

## 6.4 Reference to other sections

Additional information:

# SECTION 7 : HANDLING AND STORAGE

## 7.1 Precautions for safe handling

Protective measures:

Advice on safe handling: Avoid contact with skin, eyes and clothes. ; Avoid: Eye contact ; Avoid: Generation/formation of aerosols ; Avoid: Skin contact ; Avoid: inhalation ; In the immediate working surroundings there must be: Emergency shower installed ; In the immediate working surroundings there must be: Provide eye shower and label its location conspicuously ; Wash contaminated clothing immediately. ;

Fire preventions:

Do not eat, drink or smoke in areas where reagents are handled. ; Do not pipet by mouth ; Wear suitable one-way gloves at work ;

Advice on general occupational hygiene

Handle in accordance with good industrial hygiene and safety practice ; Observe technical data sheet. ; Remove contaminated, saturated clothing. ; Wash hands before breaks and after work. ;

## 7.2 Conditions for safe storage, including any incompatibilities

Technical measures and storage conditions:

Requirements for storage rooms and vessels: Keep container tightly closed. ; Keep-store only in original container or in properly labeled containers ;

Hints on storage assembly:

Materials to avoid:

Further information on storage conditions:

## 7.3 Specific end uses:

Recommendations on specific end uses: Observe technical data sheet. ;

# SECTION 8 : EXPOSURE CONTROLS/PERSONAL PROTECTION

## 8.1 Control parameters

Preliminary remark:

### 8.1.1 Occupational exposure limits:

- France

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 5 of 12, Revision date: 22/10/2023

---

- Spain
- Germany
- Italia
- Greece
- UK
- OSHA (USA)

8.1.2 Biological limit values (Germany):

8.1.3 Exposure limits at intended use (Germany):

8.1.4 DNEL/PNEC-values:

- DNEL worker
- DNEL consumer

DNEL remark:

- PNEC

PNEC remark:

Control parameters remark:

## **8.2 Exposure controls**

8.2.1 Appropriate engineering controls:

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 6 of 12, Revision date: 22/10/2023

8.2.2 Personal protective equipment:

**Eye / Face protection:** Safety glasses with side-shields ;

**Skin protection:** Gloves ; Laboratory coats ;

**Respiratory protection:** Ensure adequate ventilation ;

**Thermal hazards:**

8.2.3 Environmental exposure controls:

## SECTION 9 : PHYSICAL AND CHEMICAL PROPERTIES

### 9.1 Information on basic physical and chemical properties

#### Appearance

Physical state	Liquid ;
Colour	
Odour	
Odour threshold (ppm)	

	Value	Concentration (mol/L)	Method	Temperature (°C)	Pressure (kPa)	Remark
pH						
Melting point (°C)						
Freezing point (°C)						
Initial boiling point/boiling range (°C)						
Flash point (°C)						
Evaporation rate (kg/m <sup>2</sup> /h)						
Flammability (type : ) (%)						
Upper/lower flammability or explosive limits	Upper explosive limit (%)					
	Lower explosive limit (%)					
Vapour pressure (kPa)						
Vapour density (g/cm <sup>3</sup> )						
Densities	Density (g/cm <sup>3</sup> )					
	Relative density (g/cm <sup>3</sup> )					
	Bulk density (g/cm <sup>3</sup> )					
	Critical density (g/cm <sup>3</sup> )					
Solubility (Type : ) (g/L)						
Partition coefficient (log Pow) n-octanol/water at pH :						
Auto-ignition temperature (°C)						
Decomposition temperature (°C) Decomposition energy : kJ						
Viscosity	Viscosity, dynamic (poiseuille)					
	Viscosity, cinematic (cm <sup>2</sup> /s)					
Oxidising properties						
Explosive properties						

### 9.2 Other information:

No other relevant data available

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 7 of 12, Revision date: 22/10/2023

## SECTION 10 : STABILITY AND REACTIVITY

**10.1 Reactivity** This material is considered to be non-reactive under normal use conditions. ;

**10.2 Chemical stability**

**10.3 Possibility of hazardous reactions**

**10.4 Conditions to avoid:**

**10.5 Incompatible materials:**

**10.6 Hazardous decomposition products:**

Does not decompose when used for intended uses. ; Thermal decomposition can lead to the escape of irritating gases and vapors. ;

## SECTION 11 : TOXICOLOGICAL INFORMATION

Toxicokinetics, metabolism and distribution

**11.1 Information on toxicological effects**

### Substances

- **Acute toxicity**

#### Animal data:

Acute oral toxicity:

Acute dermal toxicity:

Acute inhalative toxicity:

Practical experience / human evidence:

Assessment / Classification:

General Remark:

- **Skin corrosion/irritation**

#### Animal data:

In-vitro skin test method:

In-vitro skin test result:

Assessment / Classification:

- **Eye damage/irritation**

#### Animal data:

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 8 of 12, Revision date: 22/10/2023

---

In vitro eye test method:

In vitro eye test result:

Assessment / Classification:

- **CMR effects (carcinogenicity, mutagenicity and toxicity for reproduction)**
  - Germ cell mutagenicity:

Animal data:

Assessment / Classification:

- Carcinogenicity

Practical experience / human evidence:

Animal data:

Other information:

Assessment / Classification:

- Reproductive toxicity

Practical experience / human evidence:

Animal data:

Other information:

Assessment / Classification:

Overall assessment on CMR properties:

- **Specific target organ toxicity (single exposure)**
  - STOT SE 1 and 2

Animal data:

Other information:

- STOT SE 3

Practical experience / human evidence:

Other information:

Assessment / Classification:

- **Specific target organ toxicity (repeated exposure)**

Practical experience / human evidence:

Animal data:

Assessment / Classification:

Other information

- **Aspiration hazard**



according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 9 of 12, Revision date: 22/10/2023

---

Practical experience / human evidence:

Experimental data: viscosity data: see SECTION 9.

Assessment / Classification:

Remark:

#### 11.1.1 Mixtures

No toxicological information is available for the mixture itself

## SECTION 12 : ECOLOGICAL INFORMATION

In case that test data regarding one endpoint/differentiation exist for the mixture itself, the classification is carried out according to the substance criteria (excluding biodegradation and bioaccumulation). If no test data exist, the criteria for mixture classification has to be used (calculation method); in this case the toxicological data of the ingredients are shown.

### **12.1 Aquatic toxicity:**

Acute (short-term) fish toxicity

Chronic (long-term) fish toxicity

Acute (short-term) toxicity to crustacea

Chronic (long-term) toxicity to crustacea

Acute (short-term) toxicity to algae and cyanobacteria

Toxicity to microorganisms and other aquatic plants / organisms

Assessment / Classification:

### **12.2 Persistence and degradability**

Biodegradation:

Abiotic Degradation:

Assessment / Classification:

### **12.3 Bioaccumulative potential**

Bioconcentration factor (BCF):

### **12.4 Mobility in soil**

### **12.5 Results of PBT and vPvB assessment**

### **12.6 Other adverse effects:**

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor  
 Version: UK, Page 10 of 12, Revision date: 22/10/2023

Additional ecotoxicological information:

**SECTION 13 : DISPOSAL CONSIDERATIONS**

**13.1 Waste treatment methods**

Waste treatment options: Dispose of waste according to applicable legislation. ;

**SECTION 14 : TRANSPORT INFORMATION**

ADR/RID/AND/IMDG/IATA

UN No.	
UN Proper shipping name	
Transport hazard class(es)	
Hazard label(s)	
Packing group	

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Land transport (ADR/RID)

Classification code ADR:	Special Provisions for ADR/RID:
Limited quantities for ADR/RID:	Excepted Quantities for ADR/RID:
Packing Instructions for ADR/RID:	Special packing provisions for ADR/RID:
Mixed packing provisions:	
Portable tanks and bulk containers Instructions:	
Portable tanks and bulk containers Special Provisions:	
ADR Tank Code:	ADR Tank special provisions:
Vehicle for tank carriage:	
Special provisions for carriage Packages:	
Special provisions for carriage Bulk:	
Special provisions for carriage for loading, unloading and handling:	
Special Provisions for carriage Operation:	
Hazard identification No:	Transport category (Tunnel restriction code):

Sea transport (IMDG)

Marine Pollutant:	Subsidiary risk(s) for IMDG:
Packing provisions for IMDG:	Limited quantities for IMDG:
Packing instructions for IMDG:	IBC Instructions:
IBC Provisions:	IMO tank instructions:
UN tank instructions:	Tanks and bulk Provisions:
EmS :	Stowage and segregation for IMDG:
Properties and observations:	

Inland waterway transport (ADN)

Classification Code ADN:	Special Provisions ADN:
Limited quantities ADN:	Excepted quantities ADN:
Carriage permitted:	Equipment required:
Provisions concerning loading and unloading:	Provisions concerning carriage:
Number of blue cones/lights:	Remark:

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 11 of 12, Revision date: 22/10/2023

#### Air transport (ICAO-TI / IATA-DGR)

Subsidiary risk for IATA: Excepted quantity for IATA:  
Passenger and Cargo Aircraft Limited Quantities Packing Instructions:  
Passenger and Cargo Aircraft Limited Quantities Maximal Net Quantity :  
Passenger and Cargo Aircraft Packaging Instructions :  
Passenger and Cargo Aircraft Maximal Net Quantity :  
Cargo Aircraft only Packaging Instructions : Cargo Aircraft only Maximal Net Quantity :  
ERG code: Special Provisions for IATA:

## SECTION 15 : REGULATORY INFORMATION

### **15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

#### EU regulations

- Authorisations and/or restrictions on use:

Authorisations:

Restrictions on use:

SVHC :

- Other EU regulations:
- Directive 2010/75/EC on industrial emissions

Not relevant

#### National regulations

### **15.2 Chemical Safety Assessment:**

For this mixture, no chemical safety assessment has been carried out

## SECTION 16 : OTHER INFORMATION

### **16.1 Indication of changes**

Date of the previous version:06/09/2023

Modifications:

### **16.2 Other informations**

### **16.3 Classification for mixtures and used evaluation method according to regulation (EC) 1207/2008 [CLP]:**

See SECTION 2.1 (classification).

### **16.4 Relevant R-, H- and EUH-phrases (number and full text):**

according to Regulation (EC) No 1907/2006 (REACH)

Designation / Commercial name : PSNAPAT2 pSNAP-AT2 Angiotensin receptor

Version: UK, Page 12 of 12, Revision date: 22/10/2023

---